Effects of statin therapy on chronic kidney disease patients with coronary artery disease

Hao Shen 1†, Xiaodong Chen 2†, Jingfen Lu 1, Honglin Yang 1, Yan Xu 3*, Ao Zhu 1, Xiao Zhang 1, Fulong Ye 2 and Yongchun Gu 4

Abstract

Background: Long-term persistence of statin therapy provided an ongoing reduction in mortality among patients with and without a known history of CVD, and renoprotective effect on CKD patients. Until now, very few reports are available from China to address the effects of statin therapy in CKD + CAD patients.

Methods: We compared the effects of long-term statin therapy (follow-up time 4 years) in terms of cardiovascular events, all-cause death, and cardiac death among 254 CKD patients with or without CAD.

Results: Long-term statin therapy was much more effective in the CKD + CAD patients compared with CKD patients. In the CAD + CKD patients, long-term statins showed a 22.2% reduction in the CVs rate ($P = 0.012$). With regard to the all-cause and cardiac deaths, long-term statins had significant treatment effects on the CAD + CKD patients (reduction of about 28.1% in mortality rates, $P < 0.001$). In contrast, long-term statin therapy exerted no significant influence on the clinical outcomes of the CKD-only patients.

Conclusion: Long-term statin therapy more dramatically reduced the CVs and mortality rates of the CKD patients with concomitant CAD. In contrast, CKD-only patients had a good prognosis and did not appear to require statin treatment.

Keywords: Chronic kidney disease, Statin, Cardiovascular events

Background

Chronic kidney disease (CKD) is increasing worldwide, it has been recognized as a major and independent risk factor for cardiovascular events (CVs) [1–3], such as coronary artery disease (CAD). Patients with CAD were frequently shown to have impaired renal function, which may contribute to worse clinical outcomes. On the other hand, most CKD patients die of cardiovascular diseases (CVD) than to progress to end stage kidney disease [4–6].

Statins, the 3-hydroxy 3-methyl-glutaryl coenzyme-A reductase inhibitors, are well tolerated and the first-choice agents for low-density lipoprotein cholesterol (LDL-C) reduction. They are reported to reduce CVs, including myocardial infarction, stroke, and death [7–9]. In patients with mild-to-moderate CKD, statins were found to be effective for primary prevention and to reduce cardiovascular risk [10–14]. Thus, it is believed that statins have both cardiovascular and renal benefits in prevention and treatment.

Long-term persistence of statin therapy provided an ongoing reduction in mortality among patients with and without a known history of CVD, and renoprotective effect on CKD patients [15, 16]. Until now, very few reports are available from China to address the effects of statin therapy in CKD + CAD patients. Consequently, we compare the effects of long-term statin therapy on CVs and mortality in Chinese CKD patients with or without CAD.
Methods
Study participants
Hospitalization records of 254 patients with CKD (stage3–4) + CAD, or CKD (stage3–4) only were reviewed for demographic data, cardiovascular end points, and long-term regular use of statins. Inpatients were selected from the Wujiang Affiliated Hospital of Nantong University between December, 2010 and December, 2012. Of these, 128 CKD patients were considered to have concomitant CAD if they were diagnosed with CAD by coronary angiogram (CAG), patients received a stent graft or coronary artery bypass grafting surgery according to the extent of their lesions, and 126 CKD-only patients were randomly selected for the control groups. We used a simplified MDRD equation, which is more suitable for Chinese people, to evaluate kidney functions: 186 × (serum creatinine)^{−1.154} × Age^{−0.203} × (0.742 for female). The staging of renal function was categorized according to the K/DOQI guidelines [17, 18]: stage 3 is a moderate reduction in eGFR (30–59 mL/min/1.73 m²), stage 4 is a severe reduction in eGFR (15–29 mL/min/1.73 m²).

Hospitalization records of the 254 patients were reviewed for cardiovascular end points: The primary end points (death, including cardiovascular and non-cardiovascular mortality), secondary end points (revascularization, angina, nonfatal myocardial infarction, heart failure, ischemic stroke, and hemorrhagic stroke), Long-term statin users were defined: patients who had taken medication not less than 50% of the follow-up time minus 30 days to the end of follow-up [19]. Otherwise, the patients were categorized into the no-statin group, and demographic data, included gender, age, body mass index (BMI), history of hypertension and diabetes mellitus [20]. Acute myocardial infarction, angina, and heart failure were diagnosed according to the 2008 European Society of Cardiology guidelines. Stroke was diagnosed by the 2010 Chinese guidelines for diagnosis and treatment of acute ischemic stroke [21].

Exclusion criteria included diagnosis of CAD prior to admission; long-term treatment with lipid-lowering drugs prior to admission; missing blood examination data; patients who died during the hospitalization; patients suffering from major diseases, and expected to survive less than 3 months.

Laboratory measurements
Various biochemical indexes: fasting blood glucose (FBG), triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), LDL-C, lipoprotein (a) (Lp-a), apolipoprotein A-I (ApoA-I), apolipoprotein B (ApoB), and glycedated hemoglobin (HbA1C) were measured via HPLC method [20].

Statistical analyses
Continuous and categorical data were presented as mean ± standard deviation (SD) and number (%), t-test for parametric variables and Wilcoxon tests for non-parametric variables were used to assess group differences (CKD vs CKD + CAD). Comparisons of categorical variables were performed by the Chi-square test. The long-term event-free rate was estimated using Kaplan-Meier curves, and the log-rank test was used to identify significant differences in survival rates between the two groups. A univariate Cox regression model was used to identify the potential factors that might affect the incidence of cardiovascular events. Furthermore, a multivariate Cox regression analysis was developed to determine those independent predictors. Hazard ratios and corresponding 95% confidence intervals were used to describe the intensity for the risk of cardiovascular events. All the statistical analyses were two-tailed. And P < 0.05 was considered statistically significant. All statistical analyses were performed using SAS 9.1(SAS Institute, Cary, NC, USA).

Results
Patients’ Characteristics
A total of 254 patients were examined in this research. The CAD + CKD group included 128 patients. The CKD-only group had 126 patients, respectively. Table 1 summarizes the characteristics of patients in the two groups. The oldest patients and Male gender was found more often in the CKD + CAD group. It is noteworthy that Hypertension, myocardial infarction, smoking, and angina pectoris were more common in the CKD + CAD group. There were significant differences in statin therapy: 90.6% of CKD + CAD patients took statins compared with only 46.0% of CKD patients. There was also a significant difference in other medications therapy between the two groups, such as aspirin, β-blockers, calcium-channel blockers, angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-receptor blockers (ARB). Table 2 shows the laboratory characteristics of the subjects. There was a significant difference in TG, TC, LDL-C, HDL-C, Glucose, HbA1c and DBP at baseline between the two groups, and the other parameters in the baseline characteristics were similar.

Clinical outcomes
The CKD + CAD group was found to have CVs (54.6%), all-cause death (24.2%), and cardiac death (20.3%) with the higher frequency among the two groups (Fig. 1). The incidence of CVs was lower in the CKD-only group (24.5%) compared with that of the CKD + CAD group (P < 0.001). Figure 2 shows the cardiovascular events-free survival curves through 4 years for the two groups. The log-rank test revealed that the cardiovascular events
Effects of statins on clinical outcomes
We compared the effects of statins on the clinical outcomes of the two groups of subjects. The data of Table 3 revealed that long-term statin therapy was much more effective in the CKD + CAD patients compared with CKD patients. In the CAD + CKD patients, long-term statins showed a 22.2% reduction in the CVs rate (P = 0.012). With regard to the all-cause and cardiac deaths, long-term statins had significant treatment effects on the CAD + CKD patients (reduction of about 28.1% in mortality rates, P < 0.001). In contrast, long-term statin therapy exerted no significant influence on the clinical outcomes of the CKD-only patients.

Predictors for cardiovascular events
Univariate Cox regression analysis showed that group, age, hypertension, smoking, myocardial infarction, β-blockers, aspirin, LDL-C, statin discontinuation at final therapy exerted no significant influence on the clinical outcomes of the CKD-only patients.

Multivariate Cox regression analysis, including the significant predictors above and the marginally significant predictor of myocardial infarction in the univariate model, showed that group, smoking, LDL-C, statin discontinuation were independent predictors of CVs (Table 4). The CKD-only group had the lower risk of CVs (versus CAD + CKD group: HR 0.46, 95% CI 0.25–0.59, P < 0.001. The findings indicate that the CKD group had the better long-term survival status than CAD + CKD group.

Discussion
Our study compared the effects of long-term statin treatment in CKD and CAD + CKD patients in China. In the current study, we showed that, among the Chinese CKD patients, the rate of CAD was as high as 50.4% (128/254). In particular, the all-cause and cardiac death rates of the CAD + CKD patients were about twice as high as the CKD-only patients. Thus, just as CKD is a risk factor for CAD, CAD is a risk factor for CKD, emphasizing that CAD and CKD are closely associated diseases with a reciprocal adverse impact. Our data show that long-term statin therapy can significantly improve the clinical outcomes of the CAD + CKD patients, the treatment effect of statins was much more dramatic, with remarkable reductions in the CVs rate (22.2%), all-cause death (28.1%), and cardiac death (26.3%). In contrast, no significant treatment effect of statin was observed in the CKD-only patients. In the current study, the CAD + CKD patients had a high rate of hypertension.

Table 1 The clinical characteristics at baseline

| Variables                     | CKD + CAD (n = 128) | CKD (n = 126) | P* |
|-------------------------------|---------------------|--------------|----|
| Characteristic                |                     |              |    |
| Age (years)                   | 69.7 ± 8.4          | 53.6 ± 17.8  | < 0.001 |
| Male                          | 90/128 (70.3)       | 54/126 (42.8) | < 0.001 |
| BMI (kg/m²)                   | 24.3 ± 2.1          | 23.4 ± 2.2   | 0.001 |
| Hypertension                  | 95/128 (74.2)       | 71/126 (56.3) | 0.003 |
| Diabetes mellitus             | 34/128 (26.5)       | 36/126 (28.5) | 0.72 |
| Smoking                       | 58/128 (45.3)       | 21/126 (16.6) | < 0.001 |
| Myocardial infarction         | 72/128 (56.2)       | 0/126 (0)    | < 0.001 |
| Angina pectoris               | 51/128 (39.8)       | 0/126 (0)    | < 0.001 |
| Stroke                        | 7/128 (5.4)         | 6/126 (4.7)  | 0.798 |
| Medication                    |                     |              |    |
| Calcium-channel blocker       | 45/128 (35.1)       | 64/126 (50.7) | 0.012 |
| ACEI                          | 57/128 (44.5)       | 23/126 (18.2) | < 0.001 |
| ARB                           | 46/128 (35.9)       | 66/126 (52.3) | 0.008 |
| β-blocker                     | 92/128 (71.8)       | 37/126 (28.6) | < 0.001 |
| Loop diuretic                 | 19/128 (14.8)       | 11/126 (8.7)  | 0.131 |
| Aspirin                       | 117/128 (91.4)      | 37/126 (29.3) | < 0.001 |
| Statin                        | 116/128 (90.6)      | 58/126 (46.0) | < 0.001 |

Data are presented as mean ± SD or the number and its percentage (%). Percentage = the number of each individual category divided by n

CD = coronary artery disease, CKD = chronic kidney disease, ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin-receptor blocker, BMI = body mass index

* = indicates the comparison of mean or percentage between CKD + CAD group and CKD group

Table 2 The laboratory characteristics at baseline

| Variables               | CKD + CAD (n = 128) | CKD (n = 126) | P* |
|-------------------------|---------------------|--------------|----|
| Triglycerides (mmol/l)  | 1.7 ± 1.1           | 2.5 ± 1.3    | < 0.001 |
| Total cholesterol (mmol/l) | 4.8 ± 1.3       | 6.6 ± 2.8    | < 0.001 |
| LDL-C (mmol/l)          | 6.7 ± 1.9           | 4.1 ± 2.4    | < 0.001 |
| HDL-C (mmol/l)          | 1.0 ± 0.4           | 1.3 ± 0.4    | < 0.001 |
| Glucose (mmol/l)        | 7.3 ± 4.4           | 9.1 ± 5.2    | 0.003 |
| HbA1c (%)               | 6.5 ± 1.2           | 7.9 ± 2.3    | < 0.001 |
| SBP (mmHg)              | 137.1 ± 31.2        | 139.3 ± 21.9 | 0.517 |
| DBP (mmHg)              | 78.3 ± 15.1         | 73.1 ± 10.2  | 0.001 |
| ApoA-I (g/l)            | 1.3 ± 2.8           | 1.3 ± 0.3    | 0.999 |
| ApoB (g/l)              | 1.0 ± 2.2           | 1.0 ± 0.3    | 0.999 |
| ApoA/AB                  | 1.3 ± 0.3           | 1.4 ± 0.5    | 0.054 |
| Lp (a) (ng/ml)          | 382.3 ± 326.4       | 373.4 ± 394.2 | 0.845 |

Data are presented as mean ± SD

CAD = coronary artery disease, CKD = chronic kidney disease, HbA1c = hemoglobin A1c, ApoA-I = apolipoprotein A-I, ApoB = apolipoprotein B, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, SBP = systolic blood pressure, DBP = diastolic blood pressure, Lp (a) = lipoprotein (a)

* = indicates the comparison of mean between CKD + CAD group and CKD group
smoking, myocardial infarction, and angina pectoris. The unadjusted determinants of CVs included hypertension, smoking, myocardial infarction, LDL-C level, and the use of β-blockers and aspirin. After adjustment, smoking, statin therapy, LDL-C level were significant predictors of CVs. These findings are consistent with previous reports in general [5, 6, 22].

To our knowledge, few studies have compared the effects of long-term statin therapy in the CKD patients with or without CAD from China. Some study [23, 24] compared the effects of statins on the clinical outcomes of CAD patients with or without renal insufficiency; however, there was no CKD-only patient group in their investigation. Longer-term statin therapy may exert...
more significant treatment effects, and our results show that the extent of reduction in CVs, all-cause deaths, and cardiac deaths appears to be more dramatic compared with the Japanese studies. This suggests that the Chinese CKD + CAD patients are substantially different from those in Japan. Possible reasons for the high morbidity and mortality in China include worse economic conditions, heavier labor, and insufficient medical care. Thus, in CKD + CAD patients with worse clinical outcomes like in China, long-term statin therapy can exert more dramatic treatment effects, and measures should be taken to enhance adherence to statins.

One striking discovery is that the CKD-only patients had very low all-cause or cardiac mortality, and statin therapy did not have a significant impact on the CVs and mortality rates. Statin treatment has been shown to be beneficial for CKD patients not undergoing dialysis [10, 16, 25]; however, previous studies have not separated CKD patients with or without CVD. In the current study, we selectively analyzed the CKD patients who did

### Table 3 Effects of statins on clinical outcomes

| Variables                  | Long-term statin | No statin | P       |
|----------------------------|------------------|-----------|---------|
| CKD + CAD                  |                  |           |         |
| Cardiovascular events      | 29/66 (43.9%)    | 41/62 (66.1%) | 0.012   |
| All-cause death            | 7/66 (10.6%)     | 24/62 (38.7%) | < 0.001 |
| Cardiac death              | 5/66 (7.5%)      | 21/62 (33.8%) | < 0.001 |
| CKD                        |                  |           |         |
| Cardiovascular events      | 12/35 (34.2%)    | 19/91 (20.8%) | 0.118   |
| All-cause death            | 2/35 (5.7%)      | 6/91 (6.5%) | 0.856   |
| Cardiac death              | 0/35 (0%)        | 3/91 (3.2%) | 0.56    |

Data are presented as the number and its percentage (%)

*CAD* coronary artery disease, *CKD* chronic kidney disease

* indicates the comparison of percentage between Long-term statins group and No statin group

### Table 4 Predictors for Cardiovascular events according to Cox’s proportional hazard analysis

| Variables                           | Unadjusted |          |          | Adjusted |            |          |
|-------------------------------------|------------|----------|----------|----------|------------|----------|
|                                     | HR         | 95% CI   | P        | HR       | 95% CI     | P        |
| CKD versus CKD + CAD                | 0.5        | (0.27–0.68) | < 0.001 | 0.46     | (0.25–0.59) | < 0.001 |
| Age (years)                         | 1.32       | (1.21–1.93) | < 0.001 | 1.10     | (0.95–1.04) | 0.078   |
| Male (versus female)                | 0.76       | (0.57–1.15) | 0.545    | –        | –          | –        |
| Hypertension                        | 1.61       | (1.21–2.01) | < 0.01  | 1.16     | (0.95–1.67) | 0.071   |
| Diabetes mellitus                   | 1.24       | (0.87–1.72) | 0.291    | –        | –          | –        |
| Smoking                             | 1.43       | (1.33–1.81) | < 0.01  | 1.41     | (1.09–2.11) | 0.009   |
| Myocardial infarction               | 1.18       | (1.06–1.89) | 0.048    | 1.03     | (0.91–1.35) | 0.121   |
| Angina pectoris                     | 1.07       | (0.67–1.46) | 0.32     | –        | –          | –        |
| Stroke                              | 1.53       | (0.97–3.16) | 0.221    | –        | –          | –        |
| Calcium-channel blocker             | 1.27       | (0.76–1.50) | 0.322    | –        | –          | –        |
| ACEI                                | 0.97       | (0.85–1.30) | 0.976    | –        | –          | –        |
| ARB                                 | 0.89       | (0.63–1.28) | 0.514    | –        | –          | –        |
| β-blocker                           | 1.42       | (1.12–1.89) | < 0.01  | 1.11     | (0.72–1.61) | 0.55    |
| Loop diuretic                       | 1.09       | (0.61–1.76) | 0.488    | –        | –          | –        |
| Aspirin                             | 1.98       | (1.56–2.97) | < 0.01  | 1.32     | (0.68–1.99) | 0.601   |
| Triglycerides (mmol/l)              | 1.12       | (0.72–1.81) | 0.78     | –        | –          | –        |
| Total cholesterol (mmol/l)          | 1.07       | (0.87–1.75) | 0.64     | –        | –          | –        |
| LDL-C (mmol/l)                      | 1.12       | (1.07–1.62) | < 0.001 | 1.05     | (1.01–1.25) | 0.011   |
| HDL-C (mmol/l)                      | 0.69       | (0.46–1.21) | 0.222    | –        | –          | –        |
| Glucose (mmol/l)                    | 1.23       | (0.96–1.91) | 0.52     | –        | –          | –        |
| HbA1c (%)                           | 0.96       | (0.68–1.69) | 0.771    | –        | –          | –        |
| SBP (mmHg)                          | 0.97       | (0.90–1.18) | 0.078    | –        | –          | –        |
| DBP (mmHg)                          | 1.08       | (0.97–1.39) | 0.56     | –        | –          | –        |
| Long-term statins                   | 0.22       | (0.19–0.57) | < 0.001 | 0.27     | (0.21–0.41) | < 0.001 |

*CAD* coronary artery disease, *CKD* chronic kidney disease, *ACEI* angiotensin-converting enzyme inhibitor, *ARB* angiotensin-receptor blocker, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *HbA1c* hemoglobin A1c, *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol
not have CVD at registration; these patients did not develop significantly increased CVs and mortality rates during the long follow-up period nor did they show an effective response to statin treatment. Thus, CKD patients free of CVD at baseline appear to have an excellent prognosis and, therefore, may not need statin treatment. This finding may provide a significant guideline regarding statins in CKD patients, and it warrants larger scale studies across multiple clinical centers in China.

There were several limitations in this study. Firstly, this is not a prospective study. Therefore, we need a more carefully controlled prospective study to achieve this purpose in the future. Secondly, the sample size of this study was small. Therefore, future studies that include a larger cohort of patients are necessary to corroborate our findings.

Conclusion
This study compared CKD patients with or without CAD treated with long-term statins; it provides new insights about the appropriate treatment of these two groups of patients. Long-term statin therapy more dramatically reduced the CVs and mortality rates of the CKD patients with concomitant CAD. In contrast, CKD-only patients had a good prognosis and did not appear to require statin treatment.

Abbreviations
Apo: Apolipoprotein; BMI: Body mass index; CAD: Coronary artery disease; CKD: Chronic kidney disease; CVD: Cardiovascular diseases; CVs: Cardiovascular events; DBP: Diastolic blood pressure; eGFR: Estimated glomerular filtration rate; FBG: Fasting blood glucose; HbAlc: Hemoglobin A1c; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; SBP: Systolic blood pressure; TC: Total cholesterol; TG: Triglyceride

Acknowledgements
This study was supported by the Renal Unit of the First People’s Hospital of Wujiang, Suzhou, China.

Funding
The First People’s Hospital of Wujiang (201834)

Availability of data and materials
Unfortunately, the initial data cannot be shared as it contains confidential information.

Authors’ contributions
SH and CXD planned and supervised the study. LJF, YHL, and XY contributed to data collection and enrolled patients. ZA performed the flow mediated dilatation test. ZX wrote the manuscript. YFL and GYC reviewed/edited the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved by the Committee on Human Research of Wujiang Affiliated Hospital of Nantong University. All patients signed a dedicate informed consent.

Consent for publication
All patients signed an informed consent to the anonymous use of their clinical data for research purposes at submission for treatment.  

Competing interests
The authors declare that they have no competing interests.

References
1. Said A, Desai C, Lerma EV. Chronic kidney disease[J]. Revue Médicale Suisse. 2015;61(9):374.
2. Raghib A, Kirsch J, Tang WHW. Prevention of heart failure in patients with chronic kidney disease[J]. Curr Cardiovasc Risk Rep. 2015;9(1):1–11.
3. Go AS, Chertow GM, Fang D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization[J]. N Engl J Med. 2004;351(13):1296–305.
4. Brüssolaux A, Bakris GL. Chronic kidney disease as a coronary artery disease risk equivalent[J]. Curr Cardiol Rep. 2013;15(3):1–6.
5. Tonelli M, Jose P, Curhan G, et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomized trial[J]. BMJ. 2006;332(7555):1–46.
6. Yagi H, Kawai M, Komukai K, et al. Impact of chronic kidney disease on the severity of initially diagnosed coronary artery disease and the patient prognosis in the Japanese population.[J]. Heart Vessels. 2011;26(4):370–380.
7. Azar RR, Waters DD. Prince’s prospects: statins, inflammation, and coronary risk[J]. Am Heart J. 2001;141(6):881–3.
8. Fang CH, Li JJ, Hui RT. Statin, like aspirin, should be given as early as possible in patients with acute coronary syndrome[J]. Med Hypotheses. 2005;64(1):192–6.
9. Tsai NW, Lin TK, Chang WN, et al. Statin pre-treatment is associated with lower platelet activity and favorable outcome in patients with acute non-cardio-embolic ischemic stroke[J]. Crit Care. 2011;15(4):R163.
10. Salmon SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease[J]. Ann Intern Med. 2012;157(4):263.
11. Ridker PM, Macfadyen J, Cressman M, et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (justification for the use of statins in prevention-an intervention trial evaluating rosuvastatin) trial[J]. J Am Coll Cardiol. 2010;55(12):1266–73.
12. Collins R, Armitage J, Parish S, et al. MRC/PHRC heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals[J]. Lancet. 2002;360(9326):7–22.
13. Tonelli M, Isles C, Curhan GC. Effect of pravastatin on cardiovascular events in people with chronic kidney disease[J]. ACC Curr J Rev. 2004;110(12):1557–63.
14. Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the treating to new targets (TNT) study[J]. Clin J American Soc Nephrol. 2007;2(6):1131.
15. Shealy V, Chodick G, Silber H, et al. Continuation of statin treatment and all-cause mortality a population-based cohort study[J]. Arch Intern Med. 2009;169(3):260–8.
16. Nikolic D, Banach M, Nâfâr S, et al. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?[J]. Int J Cardiol. 2013;168(6):5437–47.
17. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39(5):1–266.
18. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease.[J]. J Am Soc Nephrol. 2006;17(10):2937–44.

19. Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel.[J]. Clin Ther. 2008;30(11):2167–79.

20. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, [J]. Microgravity - Science and Technology. 2016;xviii(18):165–9.

21. Liu X, Zhang S, Liu M, et al. Chinese guidelines for endovascular management of ischemic cerebrovascular diseases.[J]. Interv Neurol. 2013; 1(3–4):171–84.

22. Seino Y, Nanjo K, Tajima N, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus.[J]. J Diab Investig. 2010;1(5):212–28.

23. Kaneko H, Yajima J, Okawa Y, et al. Effects of statin treatment in patients with coronary artery disease and chronic kidney disease.[J]. Heart Vessels. 2014;29(1):21–8.

24. Natsuaki M, Furukawa Y, Morimoto T, et al. Renal function and effect of statin therapy on cardiovascular outcomes in patients undergoing coronary revascularization (from the CREDO-Kyoto PCI/CABG registry Cohort-2).[J]. Am J Cardiol. 2012;110(11):1568–77.

25. Lardizabal JA, Deedwania PC. Benefits of statin therapy and compliance in high risk cardiovascular patients.[J]. Vasc Health Risk Manag. 2010;6:843–53.